药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Dihydromorphine
Vibrio cholerae CVD 103-HgR strain live antigen
The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Valinomycin.
Dihydromorphine
(S)-Warfarin
The risk or severity of bleeding can be increased when Valinomycin is combined with (S)-Warfarin.
Dihydromorphine
Tioclomarol
The risk or severity of bleeding can be increased when Valinomycin is combined with Tioclomarol.
Dihydromorphine
Diphenadione
The risk or severity of bleeding can be increased when Valinomycin is combined with Diphenadione.
Dihydromorphine
Clorindione
The risk or severity of bleeding can be increased when Valinomycin is combined with Clorindione.
Dihydromorphine
Fluindione
The risk or severity of bleeding can be increased when Valinomycin is combined with Fluindione.
Dihydromorphine
Ethyl biscoumacetate
The risk or severity of bleeding can be increased when Valinomycin is combined with Ethyl biscoumacetate.
Dihydromorphine
(R)-warfarin
The risk or severity of bleeding can be increased when Valinomycin is combined with (R)-warfarin.
Dihydromorphine
Coumarin
The risk or severity of bleeding can be increased when Valinomycin is combined with Coumarin.
Dihydromorphine
4-hydroxycoumarin
The risk or severity of bleeding can be increased when Valinomycin is combined with 4-hydroxycoumarin.
Dihydromorphine
Pralsetinib
The risk or severity of liver damage can be increased when Valinomycin is combined with Pralsetinib.
Dihydromorphine
Typhoid vaccine
The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Valinomycin.
Dihydromorphine
BCG vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Valinomycin.
Dihydromorphine
Picosulfuric acid
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Valinomycin.
Dihydromorphine
Belantamab mafodotin
Valinomycin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Calusterone
Berotralstat
The serum concentration of Berotralstat can be increased when it is combined with Nabiximols.
Calusterone
Satralizumab
The serum concentration of Nabiximols can be decreased when it is combined with Satralizumab.
Calusterone
Abametapir
The serum concentration of Nabiximols can be increased when it is combined with Abametapir.
Calusterone
Ubrogepant
The serum concentration of Ubrogepant can be increased when it is combined with Nabiximols.
Calusterone
Cenobamate
The serum concentration of Nabiximols can be decreased when it is combined with Cenobamate.